Zobrazeno 1 - 5
of 5
pro vyhledávání: '"KSENIA Kapitanova"'
Autor:
KSENIA Kapitanova, ML Bochaton-Piallat
Publikováno v:
Cardiovascular Research. 118
Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Swiss National Science Foundation Ksenia Kapitanova, Marie-Luce Bochaton-Piallat Department of Pathology and Immunology, Faculty of Medicine, University of Geneva,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bed637b688c9fb3e80b3c4c13febdc64
https://doi.org/10.1093/cvr/cvac066.203
https://doi.org/10.1093/cvr/cvac066.203
Autor:
Tamara Melnik, Ksenia Kapitanova, Laurent Vinet, Marie-Luce Bochaton-Piallat, Olivier Jordan, Florence Delie
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b64ea04944a681fe2c61e19744ffd0d9
https://doi.org/10.2139/ssrn.4260112
https://doi.org/10.2139/ssrn.4260112
Autor:
M. A. Abakumov, Ksenia Kapitanova, Irina B. Alieva, P. A. Mel’nikov, Anastasia S. Garanina, V.A. Naumenko
Publikováno v:
Biochemistry (Moscow). 84:729-745
Despite the progress of modern medicine, oncological diseases are still among the most common causes of death of adult populations in developed countries. The current therapeutic approaches are imperfect, and the high mortality of oncological patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1f2b5bb2284c2c6cf690386773b9723
https://doi.org/10.1134/s0006297919070058
https://doi.org/10.1134/s0006297919070058
Autor:
Vladimir P. Chekhonin, M P Valikhov, Irina B. Alieva, P. A. Mel’nikov, Daniil A. Vishnevskiy, Sergei A. Golyshev, Alexander G. Majouga, Aleksey Markov, Ksenia Kapitanova, Aleksey Nikitin, Stepan Vodopyanov, Artem Ilyasov, Maxim A. Abakumov, V.A. Naumenko, D. G. Zhukov, Anastasiia S Garanina
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 307
Developing nanocarriers that accumulate in targeted organs and are harmlessly eliminated still remains a big challenge. Nanoparticles (NP) biodistribution is governed by their size, composition, surface charge and coverage. The current thinking in bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cc17d8a78dcbe020e9b10522751c3af
https://pubmed.ncbi.nlm.nih.gov/31247280
https://pubmed.ncbi.nlm.nih.gov/31247280
Autor:
Aleksey Nikitin, Alexander G. Majouga, Daria M. Potashnikova, P. A. Mel’nikov, Irina B. Alieva, V.A. Naumenko, Artem Ilyasov, Stepan Vodopyanov, Vladimir P. Chekhonin, Ksenia Kapitanova, Daniil A. Vishnevskiy, Anastasiia S Garanina, Maxim A. Abakumov
Publikováno v:
SSRN Electronic Journal.
Recently neutrophil-based nanoparticles (NP) drug delivery systems have gained considerable attention in cancer therapy. Numerous studies have been conducted to identify optimal NP parameters for passive tumor targeting, while there is a fundamental
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bb063fa5eabbeebdc677d2e29c946af
https://doi.org/10.2139/ssrn.3473989
https://doi.org/10.2139/ssrn.3473989